Background: The main cause to chronic myeloid leukemia (CML) is a translocation between chromosome 9 and 22, resulting in the Philadelphia chromosome, containing a BCR-ABL fusion-gene that encodes a constitutively active tyrosine kinase. Imatinib, a selective inhibitor of the tyrosine kinase, is the first-line treatment for CML-patients. However, drug-resistance is an increasing problem, and the ...